CHINARES PHARMA (03320): Tasly Pharmaceutical Group's net profit attributable to shareholders in 2025 was 1.105 billion yuan, a year-on-year increase of 15.63%.

18:25 19/03/2026

China Resources Pharmaceuticals (03320) released the annual performance of Tasly Pharmaceutical Group Co., Ltd. (Tasly Pharmaceutical) as of December 31, 2025. The total operating income was RMB 8.236 billion, a decrease of 3.08% year-on-year, and the net profit attributable to shareholders of the listed company was RMB 1.105 billion, an increase of 15.63% year-on-year. Basic earnings per share were RMB 0.74. It is proposed to distribute cash dividends of RMB 1 per 10 shares (including tax).

CHINARES PHARMA (03320) announced the performance of Tasly Pharmaceutical Group Co., Ltd. (Tasly Pharmaceutical Group) for the year ended December 31, 2025. The company achieved a total operating income of RMB 8.236 billion, a decrease of 3.08% compared to the previous year, and a net profit attributable to shareholders of the listed company of RMB 1.105 billion, an increase of 15.63% compared to the previous year. Earnings per share were RMB 0.74. The company plans to distribute cash dividends, with a cash dividend of RMB 1 per 10 shares (including tax).

Wellington Management Group LLP increased its holdings of GENFLEET-B (02595) by 2.5242 million shares, with an approximate price per share of around 27.26 Hong Kong dollars.

Silchester International Investors LLP increased its holding in YUE YUEN IND (00551) by 1.31 million shares at a price of approximately HK$15.94 per share.

EPI (HOLDINGS) (00689) granted a loan facility of NZD 3 million.

Wellington Management Group LLP increased its holdings of GENFLEET-B (02595) by 2.5242 million shares, with an approximate price per share of around 27.26 Hong Kong dollars.

Silchester International Investors LLP increased its holding in YUE YUEN IND (00551) by 1.31 million shares at a price of approximately HK$15.94 per share.

EPI (HOLDINGS) (00689) granted a loan facility of NZD 3 million.